Showing results (321-330 of 464) with videos related to

Sort By:
Pageof 47
Oncogene|April 20, 2002
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathwayQin He, Dong Ik Lee, Rong Rong, et al.
NPJ Precision Oncology|November 14, 2025
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancerClaire Lin, Matthew J Hadfield, Ariana Santopietro, et al.
Oncotarget|December 17, 2013
Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCsJoshua E Allen, Bikramajit Singh Saroya, Miriam Kunkel, et al.
American Journal of Cancer Research|March 9, 2022
Preclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC)Nicholas R Liguori, Ashley Sanchez Sevilla Uruchurtu, Leiqing Zhang, et al.
Biomicrofluidics|May 9, 2012
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusingXiaole Mao, Ahmad Ahsan Nawaz, Sz-Chin Steven Lin, et al.
Molecular Cancer Therapeutics|January 16, 2015
A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective AdenovirusYanchun Ma, Sijie Hao, Shuwen Wang, et al.
Cell|November 23, 1992
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasiaM B Kastan, Q Zhan, W S el-Deiry, et al.
Oncotarget|January 15, 2015
The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activityJessica Wagner, Christina Leah Kline, Richard S Pottorf, et al.
American Journal of Cancer Research|January 12, 2026
Inhibition of ITGB6 stimulates potent anti-tumor responses in immunocompetent mouse models of head and neck squamous cell carcinoma and pancreatic adenocarcinomaWilliam J MacDonald, Praveen R Srinivasan, Maximilian Pinho-Schwermann, et al.
American Journal of Cancer Research|April 14, 2025
Reduced EZH1/2 expression in imipridone-treated cells correlates with synergy following combinations with EZH1/2 or HDAC inhibitors in diffuse glioma and other tumorsYiqun Zhang, Kelsey E Huntington, Attila A Seyhan, et al.
Pageof 47